Structure Therapeutics Inc. - American Depositary Shares (GPCR)

$39.54 0.21 (0.53%)

13:20 EDT GPCR Stock Quote Delayed 30 Minutes

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

By Alex Sirois, InvestorPlace Contributor Apr 24, 2024

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

7 Small-Cap Stocks that Wall Street Loves for Good Reason

GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023

7 Small-Cap Stocks That Wall Street Loves for Good Reason

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 68,049

Day's Range $39.16 - $40.08

52-Week Range $21.79 - $75.02

Dividend & Yield N/A (N/A)

GPCR Stock Predictions, Articles, and Structure Therapeutics Inc. - American Depositary Shares News

From InvestorPlace
From the Web

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

By Ian Cooper, InvestorPlace Contributor Dec 11, 2023

Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider.

If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names

By Ian Cooper, InvestorPlace Contributor Nov 29, 2023

As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.

Novartis aiming to develop next-generation weight-loss drugs (NYSE:NVS)

From Seeking Alpha Feb 16, 2024

Novartis (NVS) is jumping on the weight-loss bandwagon, aiming to develop next-generation anti-obesity drugs that could potentially address some of the drawback

IPO watch 2024: Which new stocks will hit the market?

From MarketBeat Jan 8, 2024

Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies.

Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now

From The Motley Fool Dec 25, 2023

It has genuine struggles ahead, but it has some actual value in hand as well.

Structure Therapeutics stock tanks amid Phase 2 obesity drug data (GPCR)

From Seeking Alpha Dec 18, 2023

Structure Therapeutics (GPCR) stock sank 35% in midday trading Monday after the company released Phase 2a data for its GLP-1 drug candidate GSBR-1290 in the treatment of obesity.

2 Biotech Stocks That Could Soar in December

From The Motley Fool Nov 26, 2023

These two biotechs have important catalysts coming up in December.

This Biotech Is Developing The Next Ozempic. Should You Buy It?

From The Motley Fool Jun 16, 2023

If it succeeds, it'll still face a battle for market share.

ADVERTISEMENT